Global Anti-tetanus Immunoglobulin Market Research Report 2022

Due to the COVID-19 pandemic, the global Anti-tetanus Immunoglobulin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-tetanus Immunoglobulin market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-tetanus Immunoglobulin landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Injection accounting for % of the Anti-tetanus Immunoglobulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Adults segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Anti-tetanus Immunoglobulin include SK Plasma, Baxalta, CSL, Octapharma, Grifols, LFB, Biotest, Kedrion and Hualan Biological Engineering, etc. In terms of revenue, the global 3 largest players have a % market share of Anti-tetanus Immunoglobulin in 2021.
This report focuses on Anti-tetanus Immunoglobulin volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-tetanus Immunoglobulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Anti-tetanus Immunoglobulin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Injection
Freeze-dried Injection
Segment by Application
Adults
Children
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
SK Plasma
Baxalta
CSL
Octapharma
Grifols
LFB
Biotest
Kedrion
Hualan Biological Engineering
Sinopharm
Hualan Bio-Engineering
Nanyue Bio-Pharmaceutical
Tonglu Bio-Pharmaceutical
Sichuan Yuanda Shuyang Pharmaceutical
Wuhan Central Plain Ruide Bio-Products
Shandong Taibang Bio-Products
Guangdong Shuanglin Bio-Pharmaceutical
Chengdu Rongsheng Pharmaceutical
Shenzhen Weiguang Bio-Products
Guizhou Taibang Bio-Products